Floatz logo

Nintedanib

Colon Adenocarcinoma

Roswell Park Cancer InstituteSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

47 Active assets in the Colon Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sun Yat-sen University
Phase 3BBB
Irinotecan
SWOG Cancer Research Network
Phase 3BBB
Eloxatin
Merck Sharp & Dohme LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

Nintedanib is also rated in:

idiopathic pulmonary fibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
pulmonary fibrosisDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →